<DOC>
	<DOCNO>NCT00028847</DOCNO>
	<brief_summary>RATIONALE : Imatinib mesylate may stop growth cancer cell block enzymes necessary cancer cell growth . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining imatinib mesylate chemotherapy may kill cancer cell . PURPOSE : Phase I/II trial study effectiveness imatinib mesylate plus cytarabine treating patient newly diagnose chronic myeloid leukemia .</brief_summary>
	<brief_title>Imatinib Mesylate Cytarabine Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose imatinib mesylate cytarabine patient newly diagnose chronic phase chronic myeloid leukemia . - Determine feasibility regimen define dose-limiting toxicity regimen treatment-related mortality 5 % patient . - Determine rate duration molecular response , complete hematological response , complete cytogenetic response patient treat regimen . - Determine time treatment failure patient treat regimen . - Determine overall survival patient treat regimen . OUTLINE : This multicenter , dose-escalation study imatinib mesylate cytarabine . Patients receive oral imatinib mesylate alone daily day 1-21 . Patients receive oral imatinib mesylate daily cytarabine IV 1-3 hour day 1-7 . Combination therapy repeat every 28-42 day 2 course . Patients receive maintenance oral imatinib mesylate daily . Treatment continue absence disease progression unacceptable toxicity . Cohorts 5-20 patient receive escalate dos imatinib mesylate cytarabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 5/5 , 5/10 , 5/20 patient experience dose-limiting toxicity . Patients follow every 6 month . PROJECTED ACCRUAL : A total 30-60 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose chronic myeloid leukemia first chronic phase ( within past 6 month ) Philadelphiachromosome positive OR bcrabl rearrangement No prior treatment within past 6 month hydroxyurea PATIENT CHARACTERISTICS : Age : 18 65 Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : No hepatic dysfunction Bilirubin le 2 time normal ALT le 4 time normal Renal : No renal dysfunction Creatinine le 2.3 mg/dL Cardiovascular : No severe cardiac dysfunction No New York Heart Association class IIIV heart disease Pulmonary : No severe pulmonary disease Other : HIV negative No severe neurologic disease No active uncontrolled infection No active malignancy within past 5 year except basal cell skin cancer stage 0 cervical cancer Not pregnant nursing PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics No concurrent allogeneic transplantation HLAA , B , DRmatched sibling donor matchedunrelated donor Chemotherapy : See Disease Characteristics Endocrine therapy : See Disease Characteristics Radiotherapy : See Disease Characteristics Surgery : See Disease Characteristics Other : No concurrent grapefruit grapefruit juice</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic myelogenous leukemia , BCR-ABL1 positive</keyword>
</DOC>